Literature DB >> 33772615

Impact of 18F-FDG PET/MR based tumor delineation in radiotherapy planning for cholangiocarcinoma.

Gauthier Delaby1,2, Bahar Ataeinia2, Jennifer Wo3, Onofrio Antonio Catalano4,5, Pedram Heidari2.   

Abstract

PURPOSE: Radiation therapy (RT) is an effective treatment for unresectable cholangiocarcinoma (CC). Accurate tumor volume delineation is critical in achieving high rates of local control while minimizing treatment-related toxicity. This study compares 18F-FDG PET/MR to MR and CT for target volume delineation for RT planning.
METHODS: We retrospectively included 22 patients with newly diagnosed unresectable primary CC who underwent 18F-FDG PET/MR for initial staging. Gross tumor volume (GTV) of the primary mass (GTVM) and lymph nodes (GTVLN) were contoured on CT images, MR images, and PET/MR fused images and compared among modalities. The dice similarity coefficient (DSC) was calculated to assess spatial coverage between different modalities.
RESULTS: GTV M PET/MR (median: 94 ml, range 16-655 ml) was significantly greater than GTV M MR (69 ml, 11-635 ml) (p = 0.0001) and GTV M CT (96 ml, 4-564 ml) (p = 0.035). There was no significant difference between GTV M CT and GTV M MR (p = 0.078). Subgroup analysis of intrahepatic and extrahepatic tumors showed that the median GTV M PET/MR was significantly greater than GTV M MR in both groups (117.5 ml, 22-655 ml vs. 102.5 ml, 22-635 ml, p = 0.004 and 37 ml, 16-303 ml vs. 34 ml, 11-207 ml, p = 0.042, respectively). The GTV LN PET/MR (8.5 ml, 1-27 ml) was significantly higher than GTV LN CT (5 ml, 4-16 ml) (p = 0.026). GTVPET/MR had the highest similarity to the GTVMR, i.e., DSCPET/MR-MR (0.82, 0.25-1.00), compared to DSC PET/MR-CT of 0.58 (0.22-0.87) and DSCMR-CT of 0.58 (0.03-0.83).
CONCLUSION: 18F-FDG PET/MR-based CC delineation yields greater GTVs and detected a higher number of positive lymph nodes compared to CT or MR, potentially improving RT planning by reducing the risk of geographic misses.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cholangiocarcinoma; Gross tumor volume; PET/MR; Radiation therapy

Mesh:

Substances:

Year:  2021        PMID: 33772615      PMCID: PMC8289745          DOI: 10.1007/s00261-021-03053-4

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  41 in total

1.  Preoperative staging of cholangiocarcinoma and biliary carcinoma using 18F-fluorodeoxyglucose positron emission tomography: a meta-analysis.

Authors:  Jing-Hong Hu; Jui-Hsiang Tang; Cheng-Hui Lin; Yin-Yi Chu; Nai-Jen Liu
Journal:  J Investig Med       Date:  2017-09-14       Impact factor: 2.895

2.  Hybrid PET/MRI-based delineation of gross tumor volume in head and neck cancer and tumor parameter analysis.

Authors:  Jie-Tao Ma; Cheng-Bo Han; Jia-He Zheng; Hong-Zan Sun; Shao-Min Zhang; Jun Xin; Qi-Yong Guo
Journal:  Nucl Med Commun       Date:  2017-07       Impact factor: 1.690

3.  Clinical utility of simultaneous whole-body 18F-FDG PET/MRI as a single-step imaging modality in the staging of primary nasopharyngeal carcinoma.

Authors:  Sheng-Chieh Chan; Chih-Hua Yeh; Tzu-Chen Yen; Shu-Hang Ng; Joseph Tung-Chieh Chang; Chien-Yu Lin; Tsang Yen-Ming; Kang-Hsing Fan; Bing-Shen Huang; Cheng-Lung Hsu; Kai-Ping Chang; Hung-Ming Wang; Chun-Ta Liao
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-03-03       Impact factor: 9.236

Review 4.  Clinical applications of (18)F-FDG PET in the management of hepatobiliary and pancreatic tumors.

Authors:  Anna Maria De Gaetano; Vittoria Rufini; Paola Castaldi; Anna Maria Gatto; Laura Filograna; Alessandro Giordano; Lorenzo Bonomo
Journal:  Abdom Imaging       Date:  2012-12

5.  Chemoradiation in patients with unresectable extrahepatic and hilar cholangiocarcinoma or at high risk for disease recurrence after resection : Analysis of treatment efficacy and failure in patients receiving postoperative or primary chemoradiation.

Authors:  D Habermehl; K Lindel; S Rieken; K Haase; B Goeppert; M W Büchler; P Schirmacher; T Welzel; J Debus; S E Combs
Journal:  Strahlenther Onkol       Date:  2012-04-13       Impact factor: 3.621

Review 6.  Intrahepatic cholangiocarcinoma: Epidemiology, risk factors, diagnosis and surgical management.

Authors:  Han Zhang; Tian Yang; Mengchao Wu; Feng Shen
Journal:  Cancer Lett       Date:  2015-09-25       Impact factor: 8.679

7.  Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.

Authors:  Theodore S Hong; Jennifer Y Wo; Beow Y Yeap; Edgar Ben-Josef; Erin I McDonnell; Lawrence S Blaszkowsky; Eunice L Kwak; Jill N Allen; Jeffrey W Clark; Lipika Goyal; Janet E Murphy; Milind M Javle; John A Wolfgang; Lorraine C Drapek; Ronald S Arellano; Harvey J Mamon; John T Mullen; Sam S Yoon; Kenneth K Tanabe; Cristina R Ferrone; David P Ryan; Thomas F DeLaney; Christopher H Crane; Andrew X Zhu
Journal:  J Clin Oncol       Date:  2015-12-14       Impact factor: 44.544

Review 8.  Multidisciplinary management of intrahepatic cholangiocarcinoma: Current approaches.

Authors:  Hanisah Guro; Jin Won Kim; YoungRok Choi; Jai Young Cho; Yoo-Seok Yoon; Ho-Seong Han
Journal:  Surg Oncol       Date:  2017-03-07       Impact factor: 3.279

9.  PET/MRI-guided GTV delineation during radiotherapy planning in patients with squamous cell carcinoma of the tongue.

Authors:  Natalia Samołyk-Kogaczewska; Ewa Sierko; Konrad Zuzda; Patryk Gugnacki; Piotr Szumowski; Małgorzata Mojsak; J Burzyńska-Śliwowska; Marek Z Wojtukiewicz; Kamil Szczecina; Dorota H Jurgilewicz
Journal:  Strahlenther Onkol       Date:  2019-06-18       Impact factor: 3.621

10.  Clinical Outcomes Using Magnetic Resonance-Guided Stereotactic Body Radiation Therapy in Patients With Locally Advanced Cholangiocarcinoma.

Authors:  Elaine Luterstein; Minsong Cao; James M Lamb; Ann Raldow; Daniel Low; Michael L Steinberg; Percy Lee
Journal:  Adv Radiat Oncol       Date:  2019-10-10
View more
  1 in total

Review 1.  Progress in Radiotherapy for Cholangiocarcinoma.

Authors:  Ningyu Wang; Ai Huang; Bohua Kuang; Yu Xiao; Yong Xiao; Hong Ma
Journal:  Front Oncol       Date:  2022-04-14       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.